Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 11 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

7(63.6%)

Phase 2

3(27.3%)

N/A

1(9.1%)

11Total

Phase 1(7)

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT00463008Not ApplicableCompleted

Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma

Role: lead

NCT00012038Phase 1Completed

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

Role: lead

NCT00006093Phase 1Completed

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

Role: lead

NCT00045539Phase 2Completed

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Role: lead

NCT00006268Phase 1Completed

Immunotoxin Therapy in Treating Patients With Malignant Glioma

Role: lead

NCT00005855Phase 1Completed

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

Role: lead

NCT00003878Phase 2Completed

Carmustine Implants in Treating Patients With Brain Metastases

Role: lead

NCT00004004Phase 1Completed

Procarbazine in Treating Patients With Recurrent Brain Tumor

Role: lead

NCT00004147Phase 1Completed

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

Role: lead

NCT00003574Phase 2Completed

Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors

Role: lead

NCT00003301Phase 1Completed

Irinotecan in Treating Patients With Recurrent Malignant Glioma

Role: lead

All 11 trials loaded